Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of ertapenem versus meropenem for serious complicated urinary tract infection
2008-003923-21Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in complicated urinary tract infection (cUTI) and acute pyelonephritis comparing Invanz with Meronem (2 arms). Primary endpoint: Favorable microbiological response assessment at the EFU/TOC visit. Started Nov 2008; status: terminated.
02
Drugs
ertapenemmeropenem
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on 2008-003923-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003923-21.